Alumis Inc. (ALMS) Stock Price & Analysis
Alumis Inc. (ALMS) closed at USD 6.82 on Thursday, October 22, 2026, up 0.15% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 6.81; the Oct 22, 2026 session ranged USD 6.66–6.95 on volume of 1,503,555 shares. Market capitalization is $882.75M, with a 52-week range of USD 4.37–31.35 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALMS.md
Key facts (ALMS)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 31.13 (range 15–46).
- Total return with dividends: 1Y +47.9% vs S&P 500 +14.9%; 5Y -48.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD -0.75, revenue estimate $1.7M.
Analysts (ALMS)
Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 31.13 (low 15, high 46).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-03 | Guggenheim | Downgrade | Buy → Neutral | |
| 2026-09-02 | Oppenheimer | Target lowered | Outperform | $55 → $37 |
| 2026-09-02 | Wells Fargo | Target lowered | Overweight | $51 → $25 |
| 2026-09-02 | Morgan Stanley | Target lowered | Overweight | $39 → $29 |
| 2026-09-02 | HC Wainwright & Co. | Upgrade | Neutral → Buy | $25 → $15 |
| 2026-08-14 | HC Wainwright & Co. | Reiterated | Neutral | $25 |
| 2026-08-03 | HC Wainwright & Co. | Reiterated | Neutral | $25 |
Total return (dividends reinvested) (ALMS)
| 1Y (from 2025-10-23) | 5Y (from 2024-06-24) | |
|---|---|---|
| Total return | +47.9% | -48.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +48.1% | -24.9% |
| Volatility (annualized) | 132.5% | 116.8% |
| Max drawdown | -80.0% (Jul 2026→Oct 2026) | -79.4% (Feb 2026→Oct 2026) |
ALMS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.75 | $-0.72 | +3.6% | $1.7M | 3 |
| Next quarter (ends Dec 2026) | $-0.72 | $-0.71 | +1.1% | $1.7M | 3 |
| Current fiscal year (ends Dec 2026) | $-3.32 | $-2.90 | +14.4% | $6.3M | 3 |
| Next fiscal year (ends Dec 2027) | $-2.87 | $-2.95 | -2.7% | $24.3M | 3 |
ALMS options: expected move
Options price a move of about ±21.3% (±$1.45) by Nov 20, 2026, which includes earnings on Nov 12, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 93.2% | ±21.3% |
| Dec 18, 2026 | 56 | 66.5% | ±21.3% |
| Jan 15, 2027 | 84 | 106.5% | ±41.2% |
| Apr 16, 2027 | 175 | 140.1% | ±75.3% |
30-day implied volatility 81.5% vs 64.5% realized over the last 30 trading days. Put/call ratio (volume) 0.38. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 6.82 |
|---|---|
| Change | ▲ 0.15% (up) |
| Previous Close | USD 6.81 |
| Open | USD 6.72 |
| Day Range | USD 6.66 – 6.95 |
| 52-Week Range | USD 4.37 – 31.35 |
| Volume | 1,503,555 shares |
| Market Cap | $882.75M |
| Exchange | NMS |
Technical Analysis (ALMS)
Nexqual's technical model rates ALMS "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 35.62 (neutral) |
| vs SMA50 | Below (USD 11.98) |
| MACD | -1.33 (negative) |
Analyst Ratings (ALMS)
Wall Street analysts rate ALMS "Buy" based on 10 analysts, with a mean price target of USD 31.13 (range USD 15–46), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 31.13 |
| High Target | USD 46 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (ALMS)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.75 |
| Revenue Estimate | $1.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.79 vs est -0.71 ▼ miss |
| 2026-03-31 | USD -0.74 vs est -0.83 ▲ beat |
| 2025-12-31 | USD -0.25 vs est -0.98 ▲ beat |
| 2025-09-30 | USD -1.06 vs est -1 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (ALMS)
| Total Revenue | $7.40M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -37.70% |
| Gross Margin | +100.00% |
| Operating Margin | -6439.89% |
| Profit Margin | +0.00% |
| ROE | -93.65% |
| Debt / Equity | 0.08 |
| Current Ratio | 6.74 |
| Total Cash | $502.29M |
| Total Debt | $36.43M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$370.18M (-1539.2% of revenue) |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (ALMS)
Nexqual rates Alumis Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Critical — Revenue -38% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $502M cash vs $36M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$370M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -94%, ROA -45.3% |
Ownership (ALMS)
| Insider Ownership | +0.53% |
|---|---|
| Institutional Ownership | +92.80% |
| Shares Outstanding | 129.44M |
| Float | 91.34M |
| Short % of Float | +13.26% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (ALMS)
Alumis Inc. is led by Martin Babler, President, CEO & Chairman, per Nexqual as of October 23, 2026 at 10:11 UTC.
| President, CEO & Chairman | Martin Babler |
|---|---|
| Chief Scientific Officer | David M. Goldstein |
| Chief Financial Officer | John R. Schroer C.F.A. |
Major Backers & Investors (ALMS)
Notable institutional backers of Alumis Inc. include Ayurmaya Capital Management Company, LP, Foresite Capital Management V, LLC, FMR, LLC, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ayurmaya Capital Management Company, LP | 11.7% |
| Foresite Capital Management V, LLC | 7.84% |
| FMR, LLC | 5.23% |
| Deep Track Capital, Lp | 4.9% |
| Samsara BioCapital, LLC | 4.9% |
| Price (T.Rowe) Associates Inc | 4.02% |
| venBio Partners LLC | 3.5% |
| Fidelity | 3.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.35% |
| Vanguard Group | 3.26% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt